Persistent Asset Partners’s Viridian Therapeutics VRDN Stock Holding History

Persistent Asset Partners’s Portfolio VRDN Stock Details VRDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$468K	Buy	+25,490	New	+$411K	0.14%	120
2026 Q1	–	Sell	-5,670	Closed	-$176K	–	483
2025 Q4	$176K	Buy	+5,670	New	+$156K	0.08%	226
2025 Q3	–	Sell	-28,032	Closed	-$392K	–	309
2025 Q2	$392K	Sell	28,032 -9,179	-25%	-$125K	0.29%	90
2025 Q1	$502K	Buy	37,211 +11,974	+47%	+$204K	0.42%	60
2024 Q4	$489K	Buy	+25,237	New	+$549K	0.41%	61

Other funds holding VRDN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Persistent Asset Partners's VRDN Position: Q2 2026 in Review

Persistent Asset Partners opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 25,490 shares worth $468K. The stake represents 0.14% of the portfolio and ranks #120 among its holdings. This is a return to the name: Persistent Asset Partners previously reported a position in VRDN as recently as Q4 2025.

Persistent Asset Partners first reported a position in VRDN in Q4 2024 and has held it in 5 quarters since. The position peaked at $502K in Q1 2025. 212 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

Persistent Asset Partners held 25,490 shares of Viridian Therapeutics worth $468K as of Q2 2026.
Viridian Therapeutics was a new Persistent Asset Partners position in Q2 2026.
Viridian Therapeutics made up 0.14% of Persistent Asset Partners's portfolio in Q2 2026, its #120 holding.
Persistent Asset Partners first reported a position in Viridian Therapeutics in Q4 2024 and has held it in 5 quarters since.
Persistent Asset Partners's Viridian Therapeutics position peaked at $502K in Q1 2025.
212 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.